Vitestro, an Utrecht, Netherlands-based developer of an autonomous blood drawing device, raised EUR12M in Series A funding.
The round was led by Sonder Capital.
The company intends to use the funds to accelerate product development, prepare EU market authorization, and initiate production.
Led by CEO Toon Overbeeke, Vitestro is advancing a device that combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion, ensuring accurate and secure blood collection. A prototype has been tested on more than 1,000 patients. Clinical studies will continue in 2023, with European market introduction anticipated in 2024.
Today Vitestro has a committed team of around 50 people with a track record in medical robotics, imaging software, AI, QA/RA and business development.
FinSMEs
21/03/2023